ESMO 24: GSK and iTeos Chalk Up Much-Needed Win For TIGIT

While oncology heavyweights Roche and Merck & Co have failed to make much headway with their in-house TIGIT offerings, hopes are high for iTeos's belrestotug in combination with GSK's checkpoint inhibitor, Jemperli, which has demonstrated promising response rates for non-small cell lung cancer in the Phase II GALAXIES Lung-201 study.